Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition of fingolimod hydrochloride and curcumol and application in preparing anti-oral-cancer medicine

A technology of fingolimod hydrochloride and its composition, applied in the field of anticancer drugs, to achieve the effects of significantly inducing migration, inhibiting cell proliferation, and enhancing cell proliferation

Active Publication Date: 2020-06-26
CENT SOUTH UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] So far, no combination of Fingolimod (FTY720) HCl and Curcumol has been used in the treatment of oral cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of fingolimod hydrochloride and curcumol and application in preparing anti-oral-cancer medicine
  • Pharmaceutical composition of fingolimod hydrochloride and curcumol and application in preparing anti-oral-cancer medicine
  • Pharmaceutical composition of fingolimod hydrochloride and curcumol and application in preparing anti-oral-cancer medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] CCK-8 method was used to detect the effect of Fingolimod (FTY720) HCl and Curcumol on the survival rate of SCC15 cells after single administration and combined preparation.

[0026] Experimental steps:

[0027] (1) Collect SCC15 cells in the logarithmic growth phase (purchased from ATCC cell bank, USA), adjust the concentration of the cell suspension, plate on a 96-well plate, add 100 μL of the cell suspension to each well, and make the cell density to be tested be 5* per well. 10 4 a / mL;

[0028] (2) Set up the apoptotic group that does not add the DMEM (Gibco, USA) complete medium of volume concentration 10% fetal bovine serum that does not add cells and the DMSO control group that does not add medicine volume concentration 0.1%, each concentration is set 3 parallel holes;

[0029] (3) After the cells adhere to the wall, add 5 μM Fingolimod (FTY720) HCl, 50 μg / ml Curcumol and 5 μM Fingolimod (FTY720) HCl and 50 μg / ml Curcumol joint preparation respectively, and pla...

Embodiment 2

[0033] The synergistic effect of different concentrations of Fingolimod (FTY720) HCl and Curcumol preparations on SCC15 cells was detected by CCK-8 method.

[0034] Experimental steps:

[0035] (1) Collect the SCC15 cells in the logarithmic growth phase, adjust the concentration of the cell suspension, plate the 96-well plate, add 100 μL of the cell suspension to each well, and make the density of the cells to be tested be 5*10 per well. 4 a / mL;

[0036] (2) A zero-adjustment group containing 10% fetal bovine serum with a volume concentration of 10% fetal bovine serum without adding cells is set, and a DMSO control group with a volume concentration of 0.1% without adding drugs is set, and 3 parallel wells are set for each concentration;

[0037] (3) After the cells adhere to the wall, add different concentrations of Fingolimod (FTY720) HCl and Curcumol (concentrations are 3μM+50μg / ml, 5μM+50μg / ml, 5μM+60μg / ml, 6μM+40μg / ml, 6μM +50μg / ml, 6μM+50μg / ml, placed in 5% CO by volume ...

Embodiment 3

[0043] The effects of Fingolimod (FTY720) HCl and Curcumol on the induction of apoptosis of SCC15 cells alone and in combination were detected by Annexin V / PI method flow cytometry.

[0044] Experimental steps:

[0045] (1) Collect SCC15 cells in the logarithmic growth phase and adjust the concentration of the cell suspension to 1*10 5 cells / mL were inoculated in a 6-well plate with a total volume of 2ml. After the cells adhered to the wall, 5 μM Fingolimod (FTY720) HCl, 50 μg / ml Curcumol, and a combined preparation of 5 μM Fingolimod (FTY720) HCl and 50 μg / ml Curcumol were added, The corresponding concentration of DMSO (5 μL) was used as the control group, which was incubated in a cell culture incubator at 37° C. for 48 hours with a volume percentage of 5% CO 2 .

[0046] (2) Collect the cells after trypsinization, centrifuge at 2000rpm, 4°C for 5min, discard the supernatant, wash the cells twice with pre-cooled DPBS (pH 7.4, Gibco, USA), and centrifuge at 2000rpm, 4°C for 5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition of fingolimod hydrochloride and curcumol and application in the preparation of an anti-oral-cancer medicine. The fingolimod hydrochloride is used combined with curcumol to obtain an unexpected synergistic effect on oral cancer treatment. Compared with independently using any one of the fingolimod hydrochloride and the curcumol, the pharmaceutical composition has higher functions of inhibiting oral cancer cell proliferation, migration and significantly inducing apoptosis, can be made into a variety of preparation forms, and has a good clinical promotion effect and development prospects with a view to clinical treatment of oral cancer patients in the future. According to the principle of the pharmaceutical composition, the combination useof fingolimod hydrochloride and the curcumol may activate the expression of various pro-apoptotic proteins of mitochondrial BH3-only, the apoptosis of the oral cancer cells is synergistically and significantly induced, and meanwhile, the combination of the two medicines further cause cell cycle arrest on the oral cancer cells and inhibit the migration and the proliferation of the oral cancer cells.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition of fingolimod hydrochloride and curcumol and its application in the preparation of anti-oral cancer drugs. It belongs to the technical field of anticancer drugs. Background technique [0002] Oral cancer is a general term for malignant tumors that occur in the oral cavity. Most of them are squamous cell carcinomas, and most of them are caused by mucous membrane mutations. It can be subdivided into gingival cancer, tongue cancer, hard and soft palate cancer, jaw cancer, mouth floor cancer, oropharyngeal cancer, salivary gland cancer, lip cancer, and maxillary sinus cancer, as well as cancers that occur in the skin and mucous membranes of the face. It is one of the more common malignant tumors in the neck, and it is a malignant tumor with a high incidence in Asia. For the treatment of oral cancer, there is still a lack of effective treatment options and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K31/352A61P35/00A61P1/02
CPCA61K31/137A61K31/352A61P35/00A61P1/02A61K2300/00
Inventor 孙曙明李亚敏赵铭日刘斌杰潘灏
Owner CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com